var data={"title":"OnabotulinumtoxinA (Botox): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">OnabotulinumtoxinA (Botox): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=onabotulinumtoxina-botox-drug-information\" class=\"drug drug_general\">see &quot;OnabotulinumtoxinA (Botox): Drug information&quot;</a> and <a href=\"topic.htm?path=onabotulinumtoxina-botox-patient-drug-information\" class=\"drug drug_patient\">see &quot;OnabotulinumtoxinA (Botox): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605655\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spread of toxin effect:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing reports indicate that the effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable with those used to treat cervical dystonia and spasticity and at lower doses.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141936\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Botox;</li>\n      <li>Botox Cosmetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141937\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Botox;</li>\n      <li>Botox Cosmetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056907\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Muscle Contracture, Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Toxin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056900\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=onabotulinumtoxina-botox-drug-information\" class=\"drug drug_general\">see &quot;OnabotulinumtoxinA (Botox): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Potency units are specific to product and assay method utilized; do not interchange botulinum toxin products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blepharospasm:</b> Children &ge;12 years and Adolescents: Botox: IM: Initial: 1.25 to 2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose may be increased up to twice the previous dose if the response from the initial dose is insufficient (ie, effect lasted &le;2 months); maximum dose per site: 5 units. Tolerance may occur if treatments are given more often than every 3 months, but the effect is not usually permanent. Maximum cumulative dose: 200 units in 30-day period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cervical dystonia:</b> Adolescents &ge;16 years: Botox: IM: For dosing guidance, the mean dose is 236 units (25th to 75th percentile range 198 to 300 units) divided among the affected muscles in patients previously treated with botulinum toxin (maximum: &le;50 units/site). Initial dose in previously untreated patients should be lower. Sequential dosing should be based on the patient's head and neck position, localization of pain, muscle hypertrophy, patient response, and previous adverse reactions. The total dose injected into sternocleidomastoid muscles should be &le;100 units to decrease the occurrence of dysphagia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Strabismus:</b> Limited data available in patients &lt;12 years of age:  <b>Note:</b> Several minutes prior to injection, administration of local anesthetic and ocular decongestant drops are recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children 2 months to 11 years (Scott 1990): Botox: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Horizontal or vertical deviations &lt;20 prism diopters:</i> Patients weight &ge;6 kg: 1.25 units into any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Horizontal or vertical deviations 20 to 50 prism diopters: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;6 kg: 1 unit into any one muscle</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight 6 to 9 kg: 1.25 units into any one muscle</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight 10 to 12.5 kg: 1.25 to 1.75 units into any one muscle</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &gt;12.5 kg: 1.25 to 2.5 units into any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Persistent VI nerve palsy of &ge;1 month duration: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;6 kg: 1 unit into the medial rectus muscle</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge; 6 kg: 1.25 units into the medial rectus muscle </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Botox: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Vertical muscles and for horizontal strabismus &lt;20 prism diopters:</i> 1.25 to 2.5 units into any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Horizontal strabismus 20 to 50 prism diopters:</i> 2.5 to 5 units into any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Persistent VI nerve palsy of &ge;1 month duration:</i> 1.25 to 2.5 units into the medial rectus muscle </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: Re-examine patient 7 to 14 days after each injection to assess the effect of that dose. Subsequent doses for patients experiencing incomplete paralysis of the target may be may be increased up to twice the previous administered dose; maximum recommended dose as a single injection for any one muscle is 25 units. Do not administer subsequent injections until the effects of the previous dose are gone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spasticity associated with cerebral palsy:</b> Limited data available; optimal dose not established: Children &gt;18 months and Adolescents: Botox: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Upper extremity:  Usual dose: 0.5 to 2 units/kg per muscle with a total dose for any one visit: &lt;13 units/kg; reported range: 0.3 to 4 units/kg per muscle; maximum total dose: 400 units (Delgado 2010; Hoare 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lower extremity: Total dose range: 4 to 8 units/kg divided into sites; maximum cumulative dose: 200 units in a 3 month interval (Botox prescribing information [Canada] 2014; Delgado 2010); for equinus foot, a total dose of 4 units/kg injected at two sites of the gastrocnemius muscle of the affected lower limb; for diplegia, an initial total dose of 6 units/kg divided between affected limbs has been used (Botox prescribing information [Canada] 2014) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> The lowest recommended dose should be used when initiating treatment (regardless of indication). In adults treated for more than one indication, the maximum cumulative dose should be &le;400 units/3 months for Botox or &le;360 units/3 months for Botox Cosmetic. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bladder dysfunction:</b> Intradetrusor:  <b>Note:</b> Prophylactic antimicrobial therapy (excluding aminoglycosides) should be administered 1 to 3 days prior to, on the day of, and for 1 to 3 days following onabotulinumtoxinA administration to decrease risk of urinary tract infection (UTI). Discontinue antiplatelet therapy at least 3 days prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Detrusor overactivity associated with neurologic condition:</i> 30 injections of 1 mL (recommended concentration: ~6.7 units/mL) for a total dose of 200 units/30 mL (maximum: 200 units); for the final injection, ~1 mL of sterile NS should be injected to ensure that the remaining medication in the needle is delivered to the bladder; may consider retreatment with diminishing effect but no sooner than 12 weeks from previous administration (median time until second treatment in studies: 42 to 48 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Overactive bladder:</i> 20 injections of 0.5 mL (recommended concentration: 10 units/mL) for a total dose of 100 units/10 mL (maximum: 100 units); for the final injection, ~1 mL of sterile NS should be injected to ensure that the remaining medication in the needle is delivered to the bladder; may consider re-treatment with diminishing effect but no sooner than 12 weeks from the previous administration (median time until second treatment in studies: ~24 weeks) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blepharospasm:</b> Botox: IM: Initial: 1.25 to 2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose may be increased up to twice the previous dose if the response from the initial dose lasted &le;2 months; maximum dose per site: 5 units. Tolerance may occur if treatments are given more often than every 3 months, but the effect is not usually permanent. Cumulative dose: &le;200 units in 30-day period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cervical dystonia:</b> Botox: IM: For dosing guidance, the mean dose is 236 units (25th to 75th percentile range 198 to 300 units) divided among the affected muscles in patients previously treated with botulinum toxin (maximum: &le;50 units/site). Initial dose in previously untreated patients should be lower. Sequential dosing should be based on the patient's head and neck position, localization of pain, muscle hypertrophy, patient response, and previous adverse reactions. The total dose injected into sternocleidomastoid muscles should be &le;100 units to decrease the occurrence of dysphagia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary axillary hyperhidrosis:</b>  Botox: Intradermal: 50 units per axilla. Injection area should be defined by standard staining techniques. Injections should be evenly distributed into multiple sites (10 to 15), administered in 0.1 to 0.2 mL aliquots, ~1 to 2 cm apart. May repeat when clinical effect diminishes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic migraine:</b> Botox: IM: Administer 5 units/0.1 mL per site. Recommended total dose is 155 units once every 12 weeks. Each 155-unit dose should be equally divided and administered bilaterally, into 31 total sites as described below (refer to prescribing information for specific diagrams of recommended injection sites): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Corrugator: 5 units to each side (2 sites) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Procerus: 5 units (1 site only) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frontalis: 10 units to each side (divided into 2 sites/side) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Temporalis: 20 units to each side (divided into 4 sites/side) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Occipitalis: 15 units to each side (divided into 3 sites/side) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cervical paraspinal: 10 units to each side (divided into 2 sites/side) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trapezius: 15 units to each side (divided into 3 sites/side) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spasticity (focal):</b> Botox: IM: Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment. In clinical trials used to support the FDA-approved labeling, total doses up to 400 units (Botox) were administered as separate injections typically divided among selected muscles; may repeat therapy at &ge;3 months with appropriate dosage based upon the clinical condition of patient at time of retreatment. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suggested guidelines for the treatment of upper limb spasticity. The lowest recommended starting dose should be used and &le;50 units/site should be administered. <b>Note:</b> Dose listed is total dose administered as individual or separate intramuscular injection(s): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adductor pollicis: 20 units (1 site)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Biceps brachii: 100 to 200 units (divided into 4 sites) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor digitorum profundus: 30 to 50 units (1 site) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor digitorum sublimes: 30 to 50 units (1 site) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor carpi radialis: 12.5 to 50 units (1 site) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor carpi ulnaris: 12.5 to 50 units (1 site) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flexor pollicis longus: 20 units (1 site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Strabismus:</b> Botox: IM: <b>Note:</b> Several minutes prior to injection, administration of local anesthetic and ocular decongestant drops are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Vertical muscles and for horizontal strabismus &lt;20 prism diopters: 1.25 to 2.5 units in any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Horizontal strabismus of 20 to 50 prism diopters: 2.5 to 5 units in any one muscle </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Persistent VI nerve palsy &ge;1 month: 1.25 to 2.5 units in the medial rectus muscle </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Re-examine patients 7 to 14 days after each injection to assess the effect of that dose. Subsequent doses for patients experiencing incomplete paralysis of the target may be increased up to twice the previous administered dose. The maximum recommended dose as a single injection for any one muscle is 25 units. Do not administer subsequent injections until the effects of the previous dose are gone. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cosmetic uses:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Reduction of glabellar lines:</b> Botox Cosmetic: Adults &le;65 years: IM: An effective dose is determined by gross observation of the patient's ability to activate the superficial muscles injected. The location, size and use of muscles may vary markedly among individuals. Inject 0.1 mL (0.4 units) dose into each of five sites, two in each corrugator muscle and one in the procerus muscle for a total dose 0.5 mL (20 units) administered no more frequently than every 3 to 4 months.   </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Reduction of lateral canthus lines:</b> Botox Cosmetic: IM: Inject 0.1 mL (4 units) into 3 injection sites per side (6 total injection points) in the lateral orbicularis oculi muscle for a total dose of 0.6 mL (24 units) administered no more frequently than every 3 months. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141917\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Botox: 100 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Botox: 200 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Botox Cosmetic: 100 units (1 ea) [contains albumin human]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Botox Cosmetic: 50 units (1 ea) [contains albumin human]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141903\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8104244\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5303lbl.pdf#page=20&amp;token=icF6Pqa2/gYMkkFB5v4zTfJ1QiqdcUOVavfoFx5eOL4bznKt8slGyUZtuEi6g3xJnb1Fkfsro3twapNQYs8G4kzzQa7jMOEoovNYVs3hAkfbJkLq7k5fbg5nmuw79c+V&amp;TOPIC_ID=13089\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5303lbl.pdf#page=20</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056910\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> For IM or intradermal administration only by individuals understanding the relevant neuromuscular and orbital anatomy and any alterations to the anatomy due to prior surgical procedures and standard electromyographic techniques. Local site reactions may be minimized by careful injection into the target muscle, using a minimal volume, and slowing the rate of injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: <b>Note:</b> Dilution concentration is dependent on indication; see product labeling for details.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Blepharospasm: </b>Administer IM using a 27- or 30-gauge needle without electromyography guidance. Avoid injecting near the levator palpebrae superioris (may decrease ptosis); avoid medial lower lid injections (may decrease diplopia). Apply pressure at the injection site to prevent ecchymosis in the soft eyelid tissues.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Cervical dystonia:</b> Administer IM using 25-, 27-, or 30-gauge needle for superficial muscles and a longer 22-gauge needle for deeper musculature; electromyography may help localize the involved muscles.  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Chronic migraines:</b> Adults: Administer IM using a 0.5-inch, 30-gauge needle to administer 5 units/0.1 mL to each of the 31 sites in the head/neck muscle areas; a 1-inch needle may be needed in the neck region for patients with thick neck muscles. All muscles except the procerus muscle (single injection only) should be injected bilaterally with half the number of  injections administered on the left side and the other half administered on the right side. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Spasticity (focal):</b> Administer IM using a 25-, 27-, or 30-gauge needle for superficial muscles and a longer 22-gauge needle for deeper musculature; electromyography or nerve stimulation may help localize the involved muscles.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Strabismus injections:</b> Administer IM into extraocular muscles utilizing the electrical activity recorded from the tip of the injections needle as a guide to placement within the target muscle. Injection without surgical exposure or EMG guidance should not be attempted. Health care providers should be familiar with EMG technique. To prepare the eye for injection, it is recommended that several drops of a local anesthetic and an ocular decongestant be given several minutes prior to injection. The volume of injection should be 0.05 to 0.15 mL per muscle. Many patients will require additional doses because of inadequate response to initial dose. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Reduction of glabellar lines (Botox Cosmetic):</b> Adults: Administer IM using a 30- to 33-gauge needle. Inject into each of 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle). Ensure injected volume/dose is accurate and where feasible keep to a minimum. Avoid injection near the levator palpebrae superioris. Lateral corrugator injections should be at least 1 cm above the bony supraorbital ridge. Do not inject toxin closer than 1 cm above the central eyebrow. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Reduction of lateral canthal lines (Botox Cosmetic):</b> Adults: Administer IM using a 30- to 33-gauge needle and give injections with the needle bevel tip up and oriented away from the eye. Inject into 3 sites per side (6 total injection points) in the lateral orbicularis oculi muscle. The first injection should be approximately 1.5 to 2.0 cm temporal to the lateral canthus and just temporal to the orbital rim. If the lines are above and below the lateral canthus, administer the next 2 injections above and below the first injection point. Inject at a similar distance from the orbital rim at a position approximately 30&deg; from the first injection. If the lines in the lateral canthal region are primarily below the lateral canthus, inject the next 2 injections below the first injection at a similar distance from the orbital rim. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intradermal: <b>Primary axillary hyperhidrosis:</b> Adults: Administer intradermally using a 30-gauge needle. Inject each dose intradermally to a depth of ~2 mm and at a 45&deg; angle with the bevel side up to minimize leakage and to ensure the injections remain intradermal. If injection sites are marked in ink, do not inject directly into areas marked in ink to avoid permanent tattoo effect. Prior to administration, injection area should be defined by standard staining techniques such as Minor's Iodine-Starch Test. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141933\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store unopened vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months or until the expiration date on the vial. After reconstitution, store in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and use within 24 hours (does not contain a preservative).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Botox 100-unit vial: The following stability information has also been reported: May be stored at room temperature for up to 5 days (Cohen 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056909\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Botox: Treatment of strabismus and blepharospasm associated with dystonia (including benign essential blepharospasm or VII nerve disorders) (FDA approved in ages &ge;12 years and adults); treatment of cervical dystonia (spasmodic torticollis) to reduce the severity of abnormal head position and neck pain (FDA approved in ages &ge;16 and adults); treatment of severe primary axillary hyperhidrosis not adequately controlled with topical treatments (FDA approved in adults); treatment of upper limb spasticity to decrease the severity of increased muscle tone in elbow, wrist, finger, and thumb flexors (FDA approved in adults); prophylaxis of chronic migraine headache (&ge;15 days/month with &ge;4 hours/day headache duration) (FDA approved in adults); treatment of overactive bladder (with symptoms of urge urinary incontinence, urgency, and frequency) with an inadequate response or intolerance to anticholinergic medication (FDA approved in adults); treatment of urinary incontinence due to detrusor overactivity associated with neurologic conditions (eg, spinal cord injury, multiple sclerosis) with an inadequate response or intolerance to anticholinergic medication (FDA approved in adult). Has also been used for treatment of  dynamic muscle contracture in pediatric cerebral palsy patients. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Botox Cosmetic: Temporary improvement in the appearance of lines and wrinkles of the face (moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity; moderate to severe lateral canthal lines associated with orbicularis oculi activity) (FDA approved in adults &le;65 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7728706\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Botulinum products are not interchangeable; potency differences may exist between the products.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6474810\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects usually occur in 1 week and may last up to several months. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bladder dysfunction:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal gait, falling, myasthenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Bacteriuria, dysuria, hematuria, increased postvoid residual urine volume (not requiring catheterization), urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (neutralizing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, drowsiness, headache, hypertonia, numbness, speech disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction: Soreness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, neck pain, stiffness, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, flu-like symptoms, rhinitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic migraines:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Exacerbation of migraine headache, facial paresis, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm, musculoskeletal pain, myalgia, myasthenia, neck pain, stiffness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower limb spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper limb spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain, myasthenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other indications (blepharospasm, forehead lines, glabellar lines, lateral canthal lines, primary axillary hyperhidrosis, reduction of glabellar lines, strabismus):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, dizziness, facial pain, facial paresis, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (nonaxillary), pruritus, skin rash, skin tightness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction: Hemorrhage, pain, soreness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis (more common with strabismus), diplopia, dry eye syndrome, ectropion, entropion, eye irritation (includes dry eye, lagophthalmos, photophobia), eyelid edema, keratitis, lacrimation, superficial punctate keratitis, vertical deviation of eyes (strabismus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms, pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: <i>Any indication:</i> Abdominal pain, acute angle closure glaucoma, alopecia, amyotrophy, anaphylaxis, anorexia, antibody development (neutralizing), aspiration pneumonia, asthma, blurred vision, brachial plexopathy, cardiac arrhythmia, corneal perforation, corneal ulceration, denervation, dermatitis, diarrhea, dysarthria, erythema, erythema multiforme, exacerbation of myasthenia gravis, eye infection, facial paresis, focal facial paralysis, hyperhidrosis, hypersensitivity reaction, hypoacusis, hypoesthesia, inflammation at injection site, jaw pain, lagophthalmos, madarosis, malaise, myalgia, myocardial infarction, paresthesia, peripheral neuropathy, pneumonia, psoriasiform eruption, radiculopathy, reduced blinking, respiratory depression, respiratory failure, retinal vein occlusion, retrobulbar hemorrhage, seizure, serum sickness, syncope, tinnitus, urinary incontinence, urticaria, vertigo, visual disturbance, voice disorder, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141922\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to any botulinum toxin preparation or any component of the formulation; infection at the proposed injection site(s).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Botox (only): Intradetrusor injection in patients with overactive bladder or detrusor overactivity associated with a neurologic condition who have a UTI; intradetrusor injection in patients with urinary retention and in patients with postvoid residual urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141907\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious and/or immediate hypersensitivity reactions (eg, anaphylaxis, serum sickness, urticaria, soft tissue edema, dyspnea) have occurred. If a reaction occurs, discontinue and institute immediate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autonomic dysreflexia: Has been observed with therapy in patients with detrusor overactivity associated with a neurologic condition; acts as stimuli to trigger an exaggerated sympathetic and parasympathetic response. Clinical presentation often includes headache, a marked increase in blood pressure, and diaphoresis; prompt treatment may be required in patients presenting with severe symptoms (eg, hypertensive crisis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Arrhythmia and MI (some fatal) have been reported following administration. Some of these patients had risk factors including preexisting cardiovascular disease. The exact relationship to onabotulinumtoxinA has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dysphagia: Common when used for cervical dystonia and may persist anywhere from 2 weeks up to 5 months after administration. In severe cases (some fatal), patients may require alternative feeding methods (eg, feeding tube). Risk factors include smaller neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae. Risk of aspiration resulting from severe dysphagia is increased in patients when swallowing is already compromised. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: Use with caution in patients with bleeding disorders and/or receiving anticoagulation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: Bronchitis and upper respiratory infection have been reported more frequently in patients treated for upper or lower limb spasticity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic toxicity: <b>[US Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence, which may develop within hours or weeks following injection. The risk is likely greatest in children treated for the unapproved use of spasticity, but symptoms can also occur in adults treated for spasticity and other conditions. Systemic effects have occurred following use in approved and unapproved uses, including doses comparable to or lower than doses used to treat cervical dystonia and upper limb spasticity.</b> Immediate medical attention required if respiratory disorders, speech, or swallowing difficulties appear.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary retention: An increased incidence of urinary retention and need for catheterization has been observed in patients receiving therapy for bladder dysfunction (overactive bladder or detrusor overactivity associated with a neurologic condition); due to the risk of urinary retention, treatment should only be used in patients able and willing to initiate post-treatment catheterization, if required. Patients with diabetes had an increased incidence of urinary retention. Patients experiencing difficulty in voiding should be instructed to consult their health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; UTI: Therapy in patients with overactive bladder increases the incidence of UTIs; clinical trials for overactive bladder excluded patients with &gt;2 UTIs in the previous 6 months and those taking chronic antibiotics for prophylaxis of recurrent UTIs. Consider risks versus benefits when contemplating use in these patients or patients experiencing recurrent UTIs during treatment. Patients with diabetes had an increased incidence of UTI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Episodic migraines: Safety and efficacy have not been established in patients with 14 or fewer headaches per month.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disease: Use with caution in patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis, Lambert-Eaton syndrome). Risk of adverse events including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Retrobulbar hemorrhages may occur from needle penetration into orbit when treating strabismus; spatial disorientation, double vision, or past-pointing may occur if one or more extraocular muscles are paralyzed. Covering the affected eye may help. Careful testing of corneal sensation, avoidance of lower lid injections, and treatment of epithelial defects are necessary. Use caution in patients with angle closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use extreme caution in patients with preexisting respiratory disease; treatment with botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Serious breathing difficulties, including respiratory failure, have been reported. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular transmission: Use with extreme caution in patients receiving other agents that may interfere with neuromuscular transmission (eg, aminoglycosides, neuromuscular-blocking agents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product may contain albumin; albumin carries an extremely remote risk for transmission of viral diseases, Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD). No cases of transmission of viral diseases, CJD, or vCJD have been identified for licensed albumin or albumin contained in other licensed products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Botulinum products (abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder dysfunction: Appropriate use: Rule out acute UTI prior to treatment; appropriate prophylactic antimicrobial therapy is required prior to, during, and following treatment. Discontinue antiplatelet therapy at least 3 days prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous tasks: May impair ability to drive and/or operate machinery due to the intended effects of treatment; if loss of strength, muscle weakness, or impaired vision occurs, patients should avoid driving or engaging in other hazardous activities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site: Use with caution if there is inflammation or excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present. Serious events (including fatalities) have been observed with direct injection into the esophagus, stomach, salivary glands, and oro-lingual-pharyngeal region. Use caution when administering in close proximity to the lungs (especially the apices); pneumothorax has been reported following administration near the thorax.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Primary axillary hyperhidrosis: Appropriate use: Evaluate for secondary causes prior to treatment (eg, hyperthyroidism). Safety and efficacy for treatment of hyperhidrosis in other areas of the body have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temporary reduction in glabellar lines: Appropriate use: Do not use more frequently than every 3 months (Canadian labeling states not to use more frequently than every 2 months). Patients with marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart were excluded from clinical trials. Use with caution in patients with surgical alterations to the facial anatomy. Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration. Spatial disorientation, double vision, or past pointing may occur if one or more extraocular muscles are paralyzed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Unapproved use: Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, including fatalities, have been reported in patients who have received injections for unapproved uses. In these cases, the reactions were not necessarily related to distant spread of toxin, but may have resulted from administration to the site of injection and/or adjacent structures; several patients had preexisting dysphagia or other significant disabilities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Upper or lower limb spasticity: Appropriate use: Safety and effectiveness of other upper or lower limb muscle groups have not been established. Treatment has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26019754\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The U.S. Food and Drug Administration (FDA) and Health Canada have issued respective communications to health care professionals alerting them of serious adverse events (including fatalities) in association with the use of onabotulinumtoxinA (Botox, Botox Cosmetic) and rimabotulinumtoxinB (Myobloc). Events reported are suggestive of botulism, indicating systemic spread of the botulinum toxin beyond the site of injection. Reactions were observed in both adult and pediatric patients treated for a variety of conditions with varying doses; however, the most serious outcomes, including respiratory failure and death, were associated with the use in children for cerebral palsy limb spasticity. The FDA has evaluated postmarketing cases and now reports that systemic and potentially fatal toxicity may result from local injection of the botulinum toxins in the treatment of other underlying conditions, such as cerebral palsy associated with limb spasticity. Monitor patients closely for signs/symptoms of systemic toxic effects (possibly occurring 1 day to several weeks after treatment) and instruct patients to seek immediate medical attention with worsening symptoms or dysphagia, dyspnea, muscle weakness, or difficulty speaking.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299790\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141912\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13089&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: OnabotulinumtoxinA may enhance the adverse neuromuscular effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the anticholinergic effect of OnabotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: May enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: OnabotulinumtoxinA may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141926\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056906\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor patients closely for signs/symptoms of systemic toxic effects (possibly occurring 1 day to several weeks after treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cervical dystonia: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) which evaluates severity, disability, and pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cerebral palsy: Modified Ashworth Scale, Tardieu Scale, Gross Motor Function Measure; treatment goals include: Improved gait and balance, facilitation of patient care, increased comfort with therapy, improved tolerance of bracing, and prevention of musculoskeletal complications  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141906\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">OnabotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by <i>Clostridium botulinum</i>, spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls. Intradetrusor injection affects efferent pathways of detrusor activity by inhibiting release of acetylcholine. Intradermal injection results in temporary sweat gland denervation, reducing local sweating.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141921\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (improvement): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Blepharospasm: ~3 to 4 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cervical dystonia: ~2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Detrusor overactivity associated with neurologic condition: ~2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reduction of glabellar lines (Botox Cosmetic): 1 to 2 days, increasing in intensity during first week </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spasticity: Focal and cerebral palsy related: &lt;2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strabismus: ~1 to 2 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Blepharospasm: ~3 to 4 months </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cervical dystonia: &le;3 to 4 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Detrusor overactivity associated with neurologic condition: ~42 to 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Primary axillary hyperhidrosis: 201 days (mean) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reduction of glabellar lines (Botox Cosmetic): ~3 to 4 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spasticity: ~3 to 3.5 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strabismus: ~2 to 6 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Blepharospasm: 1 to 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cervical dystonia: ~6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Spasticity (focal): 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strabismus: Within first week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141925\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Botox Cosmetic Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 unit (1): $397.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 unit (1): $721.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Botox Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 unit (1): $721.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 unit (1): $1,442.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038541\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Botox (AE, AR, AU, BB, BH, CH, CZ, DE, DK, ES, FI, FR, GB, HR, HU, IE, IS, IT, JO, JP, KW, LB, LK, LU, MT, NL, NO, PL, QA, SA, SE, SI, SK, VN);</li>\n      <li>Vista (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Botox Cosmetic (OnabotulinumtoxinA) [prescribing information]. Irvine, CA: Allergan, Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Botox (OnabotulinumtoxinA) [prescribing information]. Irvine, CA: Allergan, Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Botox (OnabotulinumtoxinA) [prescribing information]. Markham, Ontario: Allergan, Inc; July 7, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Botulinum Toxin,&rdquo; <i>NIH Consens Statement</i>, 1990, 12-14, 8(8):1-20. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benson J and Daugherty KK, &quot;Botulinum Toxin A in the Treatment of Sialorrhea,&quot; <i>Ann Pharmacother</i>, 2007, 41(1):79-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/17190848/pubmed\" target=\"_blank\" id=\"17190848\">17190848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charles PD, &quot;Botulinum Neurotoxin Serotype A: A Clinical Update on Non-cosmetic Uses,&quot; <i>Am J Health Syst Pharm</i>, 2004, 61(22 Suppl 6):S11-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/15598005/pubmed\" target=\"_blank\" id=\"15598005\">15598005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng CM, Chen JS, and Patel RP, &quot;Unlabeled Uses of Botulinum Toxins: A Review, Part 1,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(2):145-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/16390928 /pubmed\" target=\"_blank\" id=\"16390928 \">16390928 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng CM, Chen JS, and Patel RP, &quot;Unlabeled Uses of Botulinum Toxins: A Review, Part 2,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(3):225-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/16434781/pubmed\" target=\"_blank\" id=\"16434781\">16434781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/17687059 /pubmed\" target=\"_blank\" id=\"17687059 \">17687059 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Criswell SR, Crowner BE, and Racette BA, &quot;The Use of Botulinum Toxin Therapy for Lower-Extremity Spasticity in Children With Cerebral Palsy,&quot;  <i>Neurosurg Focus</i>, 2006, 21(2):e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/16918222 /pubmed\" target=\"_blank\" id=\"16918222 \">16918222 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2010;74(4):336-343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/20101040 /pubmed\" target=\"_blank\" id=\"20101040 \">20101040 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). <i>Cochrane Database Syst Rev</i>. 2010;(1):CD003469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/20091546 /pubmed\" target=\"_blank\" id=\"20091546 \">20091546 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russman BS, Tilton A, and Gormley ME Jr, &ldquo;Cerebral Palsy: A Rational Approach to a Treatment Protocol, and the Role of Botulinum Toxin in Treatment,&rdquo; <i>Muscle Nerve Suppl,</i> 1997, 6:S181-S193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/9826990/pubmed\" target=\"_blank\" id=\"9826990\">9826990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott AB, Magoon EH, McNeer KW, et al, &ldquo;Botulinum Treatment of Childhood Strabismus,&rdquo; <i>Ophthalmology,</i> 1990, 97(11):1434-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/onabotulinumtoxina-botox-pediatric-drug-information/abstract-text/2255516 /pubmed\" target=\"_blank\" id=\"2255516 \">2255516 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13089 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9605655\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F141936\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141937\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056907\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056900\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F141917\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F141903\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8104244\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056910\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F141933\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056909\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7728706\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6474810\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141922\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141907\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26019754\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299790\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F141912\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F141926\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056906\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141906\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F141921\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F141925\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038541\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13089|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=onabotulinumtoxina-botox-drug-information\" class=\"drug drug_general\">OnabotulinumtoxinA (Botox): Drug information</a></li><li><a href=\"topic.htm?path=onabotulinumtoxina-botox-patient-drug-information\" class=\"drug drug_patient\">OnabotulinumtoxinA (Botox): Patient drug information</a></li></ul></div></div>","javascript":null}